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Abstract
Background: B-lymphoma Moloney murine leukemia virus insertion region-1 (Bmi-1) acts as an oncogene in
various tumors, and its overexpression correlates with a poor outcome in several human cancers. Ectopic
expression of Bmi-1 can induce epithelial-mesenchymal transition (EMT) and enhance the motility and invasiveness
of human nasopharyngeal epithelial cells (NPECs), whereas silencing endogenous Bmi-1 expression can reverse
EMT and reduce the metastatic potential of nasopharyngeal cancer cells (NPCs). Mouse xenograft studies indicate
that coexpression of Bmi-1 and H-Ras in breast cancer cells can induce an aggressive and metastatic phenotype
with an unusual occurrence of brain metastasis; although, Bmi-1 overexpression did not result in oncogenic
transformation of MCF-10A cells. However, the underlying molecular mechanism of Bmi-1-mediated progression
and the metastasis of breast cancer are not fully elucidated at this time.
Results: Bmi-1 expression is more pronouncedly increased in primary cancer tissues compared to matched adjacent
non-cancerous tissues. High Bmi-1 expression is correlated with advanced clinicopathologic classifications (T, N, and M)
and clinical stages. Furthermore, a high level of Bmi-1 indicates an unfavorable overall survival and serves as a high risk
marker for breast cancer. In addition, inverse transcriptional expression levels of Bmi-1 and E-cadherin are detected
between the primary cancer tissues and the matched adjacent non-cancerous tissues. Higher Bmi-1 levels are found in
the cancer tissue, whereas the paired adjacent non-cancer tissue shows higher E-cadherin levels. Overexpression of
Bmi-1 increases the motility and invasive properties of immortalized human mammary epithelial cells, which is
concurrent with the increased expression of mesenchymal markers, the decreased expression of epithelial markers, the
stabilization of Snail and the dysregulation of the Akt/GSK3b pathway. Consistent with these observations, the
repression of Bmi-1 in highly metastatic breast cancer cells remarkably reduces cellular motility, invasion and
transformation, as well as tumorigenesis and lung metastases in nude mice. In addition, the repression of Bmi-1 reverses
the expression of EMT markers and inhibits the Akt/GSK3b/Snail pathway.
Conclusions: This study demonstrates that Bmi-1 promotes the invasion and metastasis of human breast cancer
and predicts poor survival.
Background
The processes of invasion and metastasis that cause mor-
tality in patients are extraordinarily distinctive features of
breast cancer progression [1]. Although lymph-node
metastasis, large tumor size, and poorly-differentiated
histopathological grade are commonly considered to be
established prognostic markers related to metastasis [2],
distant metastasis still occurs in 20-30% of the patients
with negative lymph-node involvement [3]. Thus far,
Human Epidermal Growth Factor Receptor 2 (HER-2/
neu) [4], c-myc [5] and HOXB9 [6] have emerged as pre-
dictors of the risk of metastasis in breast cancer. The
aberrant expression of these factors may induce the
expression of growth and angiogenic factors in tumors,
leading to increased local concentrations of these factors
within the tumor microenvironment and thus favoring
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(gene-expression profiling) has been suggested to predict
the clinical outcome more accurately than the traditional
clinical and pathological standards [7,8]. However, it is
an open question as to whether this method will enter
into the clinical routine for staging and grading [9].
Although these new markers and methods have been
implicated, the molecular mechanism of breast cancer
metastasis remains far from being fully understood due
to the heterogeneity of this cancer and represents a new
prerequisite for developing better treatment strategies.
The polycomb (PcG) proteins constitute a global sys-
tem with important roles in multi-cellular development,
stem cell biology and cancer [10]. B-lymphoma Moloney
murine leukemia virus insertion region-1 (Bmi-1), a
member of the PcG family of transcription repressors,
has emerged as a Myc-cooperating oncogene in murine
lymphomas [11,12]. Bmi-1 can not only lead human
mammary epithelial cells (HMECs) to bypass senescence
and immortalize, but it also can play a key role in
human breast cancer [13,14]. Moreover, a significant
correlation has been observed between Bmi-1 expression
and axillary lymph node metastasis in invasive ductal
b r e a s tc a n c e r[ 1 5 ] .T h e s ef i n d i n g ss u g g e s tt h a tB m i - 1
could be involved in the carcinogenesis and metastasis
of breast cancer. Although increasing evidence has
shown that Bmi-1 expression is associated with unfavor-
able prognosis [16,17], other studies have not confirmed
these findings [18,19]. Bmi-1 protein is detected in only
25% of African breast cancer patients and is associated
with a low histological grade [18]. Additionally, higher
Bmi-1 mRNA expression has been observed in early-
stage patients without lymph node metastasis [20]. In
contrast, up-regulation of Bmi-1 was shown to be asso-
ciated with the invasion of nasopharyngeal carcinomas
and to predict poor survival [21]. In colon cancer and
gastric cancer, Bmi-1 expression is significantly corre-
lated with nodal involvement, distant metastasis and
clinical stage [22-24]. Furthermore, metastatic mela-
noma tissues and cell lines show much higher expres-
sion of Bmi-1 than primary melanoma tissues and cell
lines [25]. Furthermore, knockdown of Bmi-1 contri-
butes to decreased invasiveness of cervical cancer cells
and gastric cells [4,26]. These findings indicate that
Bmi-1 contributes to increased aggressive behavior of
cancer cells. Bmi-1 overexpression can promote epithe-
lial-mesenchymal transition (EMT) in NPECs, whereas
Bmi-1 knockdown can reverse EMT and reduce the
metastasis of nasopharyngeal carcinoma cells (NPC)
[27]. Although Bmi-1 overexpression alone did not
result in oncogenic transformation of MCF-10A cells,
overexpression of Bmi-1 together with H-Ras did induce
an aggressive and metastatic phenotype, with the unu-
sual occurrence of breast cancer brain metastasis [28].
In spite of the aforementioned link between Bmi-1 and
cancer, very few studies have focused on the molecular
mechanism and clinical outcome of Bmi-1 in breast can-
cer metastasis.
The metastasis of cancer is a complex and multi-step
process, including a series of successive and dynamic
events along with alterations to cell morphology and
biological function [29]. After acquiring the ability to
undergo EMT, cancers are prone to metastasize and
establish secondary tumors at distant sites [30,31].
During EMT, epithelial cells acquire mesenchymal-like
properties, which increase cell motility, and lose
epithelial-like properties, which decrease intercellular
adhesion [32,33]. Loss of E-cadherin is a hallmark of
the invasive phase of cancer, and E-cadherin can be
repressed by certain dominant transcriptional factors,
such as Snail, ZEB, Twist, and basic Helix-Loop-Helix
family proteins (bHLH) [34-36]. Snail-induced EMT is
an important breakthrough in the study of metastasis,
providing new insights into the molecular mechanisms
of tumor invasion [37,38]. Moreover, Snail expression
is associated with E-cadherin repression and metastasis
in breast cancer cells, as well as in other cancer cell
types [39-43]. In addition to Snail, numerous agents
are involved in breast cancer EMT, such as compo-
nents of the Six1, YB-1 and miRNA-200 families
[44-46]. Therefore, it is important to understand
whether Bmi-1 can regulate EMT during breast cancer
progression and metastasis.
The present study focuses on the expression patterns
and roles of Bmi-1 in breast cancer tissues and cells to
investigate the involvement of Bmi-1 in breast cancer
metastasis. We demonstrate that Bmi-1 not only is
increased in breast cancer tissues compared with adja-
cent non-cancerous tissues but also is associated with
clinical features, such as tumor size, lymph node invol-
vement, distant metastasis and clinical stage. High Bmi-
1 expression predicts an unfavorable patient prognosis
and serves as a high risk indicator in breast cancer.
Furthermore, we also shed light on the biological impact
of Bmi-1 on the invasive and metastatic properties of
breast cancer cells. The overexpression of Bmi-1
enhances the motility and invasiveness of immortalized
HMECs, facilitates concurrent EMT-like molecular
changes, and promotes the stabilization of Snail and the
activation of the Akt/GSK3b pathway. Consistent with
these observations, repression of Bmi-1 in highly meta-
static breast cancer cells markedly reduces cell motility
and invasion, as well as tumorigenesis and lung metas-
tases in nude mice. In addition, repression of Bmi-1
reverses the expression of EMT markers and inhibits
the Akt/GSK3b pathway. Taken together, these results
provide evidence that breast cancers expressing Bmi-1
exhibit aggressive and metastatic properties.
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Increased expression of Bmi-1 in breast cancer tissues
To reveal the role of Bmi-1 in breast cancer, immunohis-
tochemistry was performed to measure Bmi-1 expression
in breast cancer tissues and adjacent non-cancerous tis-
sues. Table 1 presents the percentage of positive cells and
staining intensity of Bmi-1 expression in relation to clini-
copathologic features. Bmi-1 expression was significantly
increased in primary cancer tissues compared with
matched adjacent non-cancerous tissues (c
2 = 20.237, ***P
< 0.001, Table 2). Only 35.9% (14 of 39) of matched adja-
cent non-cancerous tissues displayed high expression of
Bmi-1, and the remaining tissues (64.1%, 25 of 39) were
scored as having no or low expression of Bmi-1(Figure 1
A, B). However, as many as 72.2% (182 of 252) of the can-
cer tissues were defined as manifesting high Bmi-1 expres-
sion (Figure 1 C, D). Positive staining was observed in
96.5% (241) of the cases. It was noted that more intense
staining was observed in cancer tissues than the adjacent
hyperplastic lobular glandules (Figure 1 E, F, G). Interest-
ingly, Bmi-1 could be detected in both the nuclei and cyto-
plasm in the adjacent non-cancer cells but was mainly
localized to the nuclei of cancer cells (Figure 1 E, F, G).
Among the adjacent non-cancerous tissues, no Bmi-1 sig-
nal was detected by staining in 30.8% (12 of 39) of the
samples. Only 28.2% (11 of 39) of the samples showed
nuclear staining, and the remaining 41.0% (16 of 39) of the
samples exhibited cytoplasmic staining. Of the cancer tis-
sues, however, 75.4% (190 of 252) of the samples were
stained in the nucleus and 24.6% (62 of 252) in the cyto-
plasm. These results indicate that Bmi-1 protein seems to
be localized in the nucleus of the majority of breast cancer
cells and in the cytoplasm of most non-cancer cells.
Correlation between Bmi-1 expression and clinical
aggressiveness of breast cancer
We further examined possible correlations between Bmi-1
expression profiles and the patients’ clinicopathologic
characteristics. As presented in Table 3, our analysis of
252 primary breast cancer cases revealed that Bmi-1
expression was strongly correlated with larger tumor size
(P < ***0.001), lymph node involvement (P < ***0.001), dis-
tant metastasis (P < ***0.001) and advanced clinical stage
(P < ***0.001). These observations suggested a correlation
between increased Bmi-1 expression and clinical progres-
sion in breast cancer. However, no evident correlations
were observed between Bmi-1 expression profiles and
other clinical/laboratory features, including age, estrogen
receptor (ER), progesterone receptor (PR) and HER-2.
High Bmi-1 expression is associated with an unfavorable
prognosis
The characteristics of breast cancer patients relevant to
overall survival are shown in Additional file 1, table S1.
As expected, the clinicopathologic classification (T, N,
M) and clinical stage were important prognostic indica-
tors in breast cancer (P < ***0.001, respectively). The
presence of PR also appeared to have a clinical prognos-
tic value (P = **0.002), but age and expression of ER or
HER-2 did not. The overall survival (OS) was 97.1%
(232 of 239) after the first year of follow-up, 86.6% (207
of 239) after the second year, 77.0% (184 of 239) after
the third year, 71.1% (170 of 239) after the fourth year
and 49.4% (118 of 239) after the fifth year.
As shown in Additional file 1, table S1, Bmi-1 expression
displayed a significant correlation with patient survival sta-
tus. The overall survival rate, assessed by the Kaplan-
Meier method, was 85.1% (57 of 67) in the low expression
group (mean follow-up period = 55.34 months), whereas it
was only 59.9% (103 of 172) in the high expression group
(mean follow-up period = 49.45 months) (Figure 2A).
Because there were strong associations between the Bmi-1
status and clinicopathologic parameters, the overall survi-
val might be further distinguished based on Bmi-1 expres-
sion and adjusting the status based on the
clinicopathologic parameters. Consistent with previous
data [47], 20.4% of the cases (30 of 147) displayed a promi-




-). The outcome was not significantly different between
the patients with high and low Bmi-1 expression (Figure
2B, P = 0.483). The overall survival rate in the TNP sub-
group was 70% in the low expression group (7 of 10) com-
pared to 75% (15 of 20) in the high expression group.
Next, a subset analysis was carried out, in which we
divided the patients into the ER negative and positive
groups based on levels of Bmi-1 expression. Interestingly,
according to the subset analysis, the impact on the out-
come associated with high Bmi-1 expression continued to
be more unfavorable in both the ER-negative and -positive
groups (Figure 2 C, P=* * 0 . 0 0 3 ;D ,P=* 0 . 0 4 1 ). In ER-
negative patients, the survival rate was 84.2% (32 out of
38) in patients with low Bmi-1 expression and 53.8% (43
out of 80) in those with high expression. Similarly, the sur-
vival rate was clearly different in the ER-positive subgroup.
The survival rate was 86.2% (25 out of 29) in patients with
low Bmi-1 expression and 65.2% (60 out of 92) in those
with high expression. Similar results were obtained for the
PR-negative and -positive groups (Figure 2 E, P = **0.010;
F, P = *0.028). The survival rate in PR-negative patients
was 79.3% (23 out of 29) in those with low Bmi-1 expres-
sion, in contrast to 47.4% (36 out of 76) in the high
expression group. Likewise, the survival rate was 89.5% (34
out of 38) in those with low Bmi-1 expression compared
to 69.8% (67 out of 96) in the high expression subset
within the PR-positive subgroup. However, the overall sur-
vival was not obviously different based on Bmi-1 expres-
sion in the HER-2-negative subgroup (Figure 2G, P=
0.701), although the outcome was much better in patients
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features
Percentage of Positive Cells Staining Intensity
12341 2 3 4
NNNNN N N N
(%) (%) (%) (%) (%) (%) (%) (%)
Age
≤45 year 11 38 20 30 5 33 35 26
(11.1) (38.4) (20.2) (30.3) (5.1) (33.3) (35.4) (26.3)
>45 year 16 40 21 64 5 46 54 36
(11.3) (28.4) (14.9) (45.4) (3.5) (32.6) (38.3) (25.5)
T Classification
T1 8 21 0 16 5 23 8 9
(17.8) (46.7) (0.0) (35.6) (11.1) (51.1) (17.8) (20.0)
T2 16 36 23 60 4 45 52 34
(11.9) (26.7) (17.0) (44.4) (3.0) (33.3) (38.5) (25.2)
T 3 4 1 61 41 8292 6 1 5
(7.7) (30.8) (26.9) (34.6) (3.8) (17.3) (50.0) (28.8)
T 4 07580 5 9 6
(0.0) (35.0) (25.0) (40.0) (0.0) (25.0) (45.0) (30.0)
N Classification
N0 18 35 6 31 6 44 24 16
(20.0) (38.9) (6.7) (34.4) (6.7) (48.9) (26.7) (17.8)
N1 10 35 28 59 5 30 57 40
(7.6) (26.5) (21.2) (44.7) (3.8) (22.7) (43.2) (30.3)
N 2 0661 0 0 5 1 0 7
(0.0) (27.3) (27.3) (45.5) (0.0) (22.7) (45.5) (31.8)
N 3 04220 3 4 1
(0.0) (50.0) (25.0) (25.0) (0.0) (37.5) (50.0) (12.5)
M Classification
M0 27 67 30 83 10 72 79 46
(13.0) (32.4) (14.5) (40.1) (4.8) (34.8) (38.2) (22.2)
M1 1 13 12 19 1 10 16 18
(2.2) (28.9) (26.7) (42.2) (2.2) (22.2) (35.6) (40.0)
Clinical Stage
I 3 14 0 6 2 16 2 3
(13.0) (60.9) (0.0) (26.1) (8.7) (69.6) (8.7) (13.0)
II 21 33 6 34 7 41 30 16
(22.3) (35.1) (6.4) (36.2) (7.4) (43.6) (31.9) (17.0)
III 3 20 24 43 1 15 47 17
(3.3) (22.2) (26.7) (47.8) (1.1) (16.7) (52.2) (30.0)
IV 1 13 12 19 1 10 16 18
(2.2) (28.9) (26.7) (42.2) (2.2) (22.2) (35.6) (40.0)
ER Presence
Negative 19 37 23 42 8 39 42 32
(15.7) (30.6) (19.0) (32.7) (6.6) (32.2) (34.7) (26.4)
Positive 9 43 19 60 3 43 53 32
(6.9) (32.8) (14.5) (45.8) (2.3) (32.8) (40.5) (24.4)
PR Presence
Negative 16 30 23 38 5 33 40 29
(15.0) (28.0) (21.5) (35.5) (4.7) (30.8) (37.4) (27.1)
Positive 12 50 19 64 6 49 55 35
(8.3) (34.5) (13.1) (44.1) (4.1) (33.8) (37.9) (24.1)
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group (Figure 2H, P = *0.018). At the time of Bmi-1 analy-
sis, 17.6% (3 out of 17) of HER-2-negative patients died
with low Bmi-1 expression compared to 26.7% (8 out of
30) of HER-2-negative patients with high Bmi-1 expres-
sion. However, the survival rate was 88.9% (24 of 27) in
the low Bmi-1 expression subset and 63.0% (46 of 73) in
the high expression subset within the HER-2-positive sub-
group. Because only a small number of cases showed low
Bmi-1 expression and T3/4 classification (N = 9), N2/3
classification (N = 2), M1 classification (N = 2) and clinical
stage III/IV (N = 6) (Table 3), the overall survivals were
not analyzed stratified by these parameters. In addition,
only 7 samples exhibited high Bmi-1 expression and stage
I (Table 3), so the role of Bmi-1 in overall survival was not
examined in the stage I subgroup. As shown in Figure 3,
significantly different outcomes based on Bmi-1 expres-
sion were compared in patient subgroups with T1 (Figure
3A, P = **0.006)a n dT 2 + 3 + 4( F i g u r e3 B ,P = *0.034).
When the tumor was less than 2 cm (T1 classification),
the survival rate was 96.0% (24 of 25) in the low expres-
sion subset in contrast to 63.2% (12 of 19) in the high
expression subset. Similarly, the survival rate was 78.6%
(33 of 42) in the low expression subset compared to 59.5%
(91 of 153) in the high expression subset when the tumors
were larger than 2 cm (T2+3+4 classification). However,
no obvious difference was observed when Bmi-1 expres-
s i o nw a sc o m p a r e di nt h eN 0a n dN 1 + 2 + 3s u b g r o u p s
(Figure 3 C, P = 0.061,D ,P = 0.248). When the patients
with an N0 classification were analyzed, the survival rate
was 91.3% (42 of 46) in the low Bmi-1 expression group
and 74.4% (29 of 39) in the high expression group. How-
ever, when the patients with N1+2+3 classifications were
analyzed, the survival rate was 71.4% (15 of 21) in the low
expression group and 55.6% (74 of 133) in the high
expression group. In our study, 26.7% (52 of 195) of
patients had died in the M0 group at the time of analysis,
and the patients with low Bmi-1 expression showed longer
survival times (Figure 3E, P = *0.018). The survival rate
was 84.8% (56 of 66) in the low Bmi-1 expression group in
contrast to 67.4% (87 of 129) in the high Bmi-1 expression
group. A similar result was found in patients with stage II/
III/IV, according to the Bmi-1 expression (Figure 3F, P=
**0.009). The survival rate was 80.8% (42 of 52) in the low
Bmi-1 expression subset compared to 58.8% (97 of 165) in
the high Bmi-1 expression subset. Taken together, these
T a b l e1T h ep e r c e n t a g eo fp o s i t i v ec e l l sa n ds t a i n i n gi n t e n sity of Bmi-1 expression related to clinicopathologic fea-
tures (Continued)
HER-2 Presence
Negative 9 12 8 22 4 17 14 16
(17.6) (23.5) (15.7) (43.1) (7.8) (3.3) (27.5) (31.4)
Positive 12 30 16 50 5 34 38 31
(11.1) (27.8) (14.8) (46.3) (4.6) (31.5) (35.2) (28.7)
Four categories of the percentage of positive cells: 1: ≤5%; 2: 6%-35%; 3: 36%-70%; 4: ≥71% (40X). Four categories of the staining intensity: 1: negative; 2: weak;
3: moderate; 4: strong.
Table 2 Difference of Bmi-1 expression between breast




N (%) N (%)
Tissues 20.237 <0.001
Non-cancer 25 (64.1) 14 (35.9)
Cancer 70 (27.8) 182 (72.2)
Four categories of the percentage of positive cells: 1: ≤5%; 2: 6%-35%; 3: 36%-
70%; 4: ≥71% (40X). Four categories of the staining intensity: 1: negative; 2:
weak; 3: moderate; 4: strong.
Final score = score of percentage of positive cells × score of staining intensity.
If the final score was >4, Bmi-1 expression was considered high, otherwise,
Bmi-1 expression was considered low.
Figure 1 Increased expression of Bmi-1 in breast cancer
tissues. (A, B) Bmi-1 showed no or weak staining in the adjacent
non-cancerous tissue. (C, D) Strong Bmi-1 staining was detected in
the primary breast cancer tissue. (E, F, J) Cancer showed high Bmi-1
expression and nuclear staining, whereas the adjacent mammary
gland lobule showed low expression and cytoplasmic staining (100X
and 400X).
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prognosis in patients with breast cancer.
Analyses of relative risks (RRs) indicative of Bmi-1’s role
in the prognosis of breast cancer
In our analyses, we defined a relative risk of 1.000 as the
baseline in patients with the following characteristics:
age (≤45 years), T1, N0, M0, clinical stage I, low Bmi-1
expression and the absence of ER, PR and HER-2. To
determine if Bmi-1 could serve as a risk factor with clin-
ical usefulness, Cox regression proportional hazard ana-
lyses were used to examine the relative risk. As seen in
Table 4, univariate Cox regression analyses revealed that
a high level of Bmi-1 was associated with a significantly
increased risk of death in breast cancer patients (***P=
0.001). The relative risk increased by almost 4-fold in
patients with high Bmi-1 expression compared to those
with low Bmi-1 expression (Table 4). As expected, large
tumor size (T3, *P = 0.013; T4, ***P < 0.001), lymph
node involvement (N1, P = **0.002;N 2 ,* * * P < 0.001),
distant metastasis (M1, ***P < 0.001) and advanced clini-
cal stage (III,*P < 0.025;I V ,* * P=0 . 0 0 3 ) were also sig-
nificant unfavorable prognostic factors. However, the
presence of PR was a favorable prognostic factor (**P=
0.003), although the presence of ER and HER-2 did not
predict the favorable or unfavorable survival (Table 4).
The clinical stage, a comprehensive index reflecting T,
N, and M classifications, is the most commonly used
prognostic factor in the clinic. After adjustment for con-
founding factors, Bmi-1 was found to predict poor survi-
val by multivariate Cox regression analyses when clinical
stage, PR presence and Bmi-1 expression were included
(*P = 0.042). Moreover, advanced clinical stage still pre-
dicted unfavorable prognosis (IV,*P = 0.014). PR was
also identified as a potential prognostic factor by multi-
variate Cox regression analysis (**P = 0.007)( T a b l e5 ) .
Thus, our findings indicate that Bmi-1 protein expres-
sion has a significant correlation with the prognosis of
breast cancer.
Exogenous expression of Bmi-1 enhances cell motility
and invasion of immortalized HMECs
Cell motility and invasion are indispensable for cancer
metastasis. Because Bmi-1 expression was correlated
with larger tumor size, lymph node involvement, distant
metastasis and advanced clinical stage in breast cancer
tissues, we hypothesized that Bmi-1 may regulate the
progression of breast cancer. Because we were interested
in the expression status of Bmi-1 in normal and breast
cancer cells, western blotting was performed to measure
Bmi-1 protein levels. Bmi-1 expression was low in p16-
negative immortalized 76N-TERT and MCF-10A cells
[13,47] and moderate in 76R-30 cells, whereas it was
abundant in all breast cancer cell lines analyzed, includ-
ing SK-BR-3, ZR-75-30, BCAP-37 and MDA-MB-435S
(Figure 4A). To address the above-mentioned hypoth-
esis, a Bmi-1 expression plasmid was stably transfected
into immortalized HMECs (76N-TERT and MCF-10A)
to examine the role of Bmi-1 in the progression of
breast cancer (Figure 4B). Bmi-1 did not affect the pro-
liferation of immortalized HMECs (Figure 4C). Boyden
chamber and wound healing assays were performed to
determine the potential for Bmi-1 to induce cell motility
and invasion. The results showed that the overexpres-
sion of Bmi-1 increased cell invasion compared to the
control (Figure 4D). Meanwhile, the overexpression of
Table 3 Correlation between Bmi-1 expression and the
clinicopathologic features of breast cancer
Bmi-1 Expression Total c
2 P-value
Low High
N (%) N (%) N (%)
Age 0.36 0.551
≤45 year 26 (26.3) 73 (73.7) 99 (41.2)
>45 year 42 (29.8) 99 (70.2) 141 (58.8)
T Classification 30.92 <0.001
T1 26 (57.8) 19 (42.2) 45 (17.9)
T2 35 (25.9) 100 (74.1) 135 (53.6)
T3 9 (17.3) 43 (82.7) 52 (20.6)
T4 0 (0.0) 20 (100.0) 20 (7.9)
N Classification 46.45 <0.001
N0 48 (53.3) 42 (46.7) 90 (35.7)
N1 20 (15.2) 112 (84.8) 132 (52.4)
N2 0 (0.0) 22 (100.0) 22 (8.7)
N3 2 (25.0) 6 (75.0) 8 (3.2)
M Classification 14.87 <0.001
M0 68 (32.9) 139 (67.1) 207 (82.7)
M1 2 (4.4) 43 (95.6) 45 (17.9)
Clinical Stage 82.06 <0.001
I 16 (69.6) 7 (30.4) 23 (9.1)
II 48 (51.1) 46 (48.9) 94 (37.3)
III 4 (4.4) 86 (95.6) 90 (35.7)
IV 2 (4.4) 43 (95.6) 45 (17.9)
ER Presence 1.53 0.217
Negative 38 (31.4) 83 (68.6) 121 (48.0)
Positive 32 (24.4) 99 (75.6) 131 (52.0)
PR Presence 0.04 0.837
Negative 29 (27.1) 78 (72.9) 107 (42.5)
Positive 41 (28.3) 104 (71.7) 145 (57.5)
HER-2 Presence 0.71 0.400
Negative 17 (33.3) 34 (66.7) 51 (32.1)
Positive 29 (26.9) 79 (73.1) 108 (67.9)
Four categories of the percentage of positive cells: 1: ≤5%; 2: 6%-35%; 3: 36%-
70%; 4: ≥71% (40X).
Four categories of the staining intensity: 1: negative; 2: weak; 3: moderate;
4: strong.
Final score = score of percentage of positive cells × score of staining intensity.
If the final score was >4, Bmi-1 expression was considered high, otherwise,
Bmi-1 expression was considered low.
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Page 6 of 23Figure 2 Influence of Bmi-1 expression on the overall survival. (A)The cumulative overall survival exhibited a significant difference based on
Bmi-1 expression, assessed by Kaplan-Meier curves in primary breast cancer tissues (***P = 0.001). (B) No difference in the overall survival curve
was observed according to Bmi-1 expression in the triple negative phenotype (TNP, ER
-,P R
-, and HER-2
-) subgroup (P = 0.483). (C, D, E, F) High
Bmi-1 expression was correlated with unfavorable prognosis irrelevant of the presence of ER (**P = 0.003, *P = 0.041) or PR (**P = 0.010, *P =
0.028). (G, H) The survival curves were significantly different according to Bmi-1 expression in the HER-2 positive panel (*P = 0.018), but not in
HER-2 negative panel (P = 0.701).
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Page 7 of 23Figure 3 Kaplan-Meier curves of overall survival stratified by Bmi-1 status according TNM classification. (A, B) In each panel of patients
with different tumor size, the overall survival was significantly shorter in the high Bmi-1 expression group than in the other group. (C, D) No
obvious difference was seen according to the Bmi-1 expression in the N0 (C, P = 0.061) and N1+2+3 (D, P = 0.248) patients subgroups. (E, F) In
the M0 panel and clinical stage II+III+IV panel, the overall survival was significantly shorter in patients with high Bmi-1 expression compared to
those with low expression (E,* P = 0.018; F, P = **0.009).
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Page 8 of 23Bmi-1 could advance the wound healing process, by
promoting the quicker closure of a ‘’wound’’ scratched
into a confluent epithelial monolayer (Figure 4E). Pooled
populations of cells expressing Bmi-1 or vector were
analyzed for a transformed phenotype using soft agar
and Matrigel assays. The 3-D Matrigel assay indicated
that the expression of Bmi-1 failed to transform the
morphology of immortalized HMECs. No irregular
branched structures indicative transformed phenotypes
were observed, other than normal spherical acini (data
not shown). To further confirm the in vitro transforma-
tion potential, the immortalized HMEC-derived cells
were seeded in soft agar. Cells expressing either Bmi-1
or vector did not exhibit anchorage-independent growth
(data not shown). These observations indicate that Bmi-
1 does promote cell motility and invasion, but Bmi-1
alone is insufficient to transform immortalized HMECs.
Suppression of Bmi-1 represses cellular motility, invasion
and transformation
To further identify the role of Bmi-1 in the progression of
cancer, a short hairpin RNA for Bmi-1 was generated to
reduce Bmi-1 expression stably and efficiently in the
MDA-MB-435S cell line (Figure 5A), a highly metastatic
breast cancer cell line [48] with high Bmi-1 expression
(Figure 5A). As expected, p16INK4, a Bmi-1 target gene
[21], was up-regulated in the Bmi-1 knockdown cells.
However, the proliferation rate did not show an obvious
alteration in response to Bmi-1 repression (Figure 5B).
The Boyden chamber invasion assay and the scratch
wound healing assay revealed that the motility and inva-
siveness of MDA-MB-435S cells were dramatically ham-
pered by the ablation of Bmi-1 (Figure 5C, D). In
addition, the growth of colonies in soft agar, as an indica-
tion of in vitro cellular transformation, were less in fre-
quent and smaller in size, which indicated that the
depletion of Bmi-1 caused the marked inhibition of
anchorage-independent growth ability (Figure 5E).
Furthermore, Bmi-1 repression caused the disappearance
of the irregular, branched structures in Matrigel cultures,
which characterize the invasive phonotype (Figure 5F).
Our results suggest that the repression of Bmi-1 could
decrease cell motility, invasion and transformation.
Repression of Bmi-1 slows tumor progression and
reduces spontaneous lung metastasis in nude mice
To further evaluate the effects of Bmi-1 on the develop-
ment of breast cancer, MDA-MB-435S/shBmi-12# and
MDA-MB-435S/shScr cells were injected into the fat
pad of nude mice. Macroscopic xenografts were
o b s e r v e di nt h ef a tp a do fn u d em i c ea f t e rt w ow e e k s .
The tumors arising from injection of MDA-MB-435S/
Table 4 Univariate Cox-regression analysis of different
prognostic parameters in patients
RR 95% CI P-value
Age
≤45 year 1.000
>45 year 1.057 0.846-1.321 0.624
T Classification
T1 1.000
T2 1.534 0.713-3.301 0.274
T3 2.841 1.251-6.454 0.013
T4 7.822 3.294-18.861 <0.001
N Classification
N0 1.000
N1 2.597 1.431-4.713 0.002
N2 7.621 3.667-15.836 <0.001
N3 2.846 0.646-12.551 0.167
M Classification
M0 1.000
M1 3.039 1.903-4.853 <0.001
Clinical Stage
I 1.000
II 5.429 0.728-40.465 0.099
III 9.750 1.330-71.481 0.025
IV 20.065 2.724-147.736 0.003
ER Presence
Negative 1.000
Positive 0.758 0.486-1.183 0.223
PR Presence
Negative 1.000
Positive 0.511 0.327-0.800 0.003
HER-2 Presence
Negative 1.000
Positive 1.347 0.675-2.689 0.398
Bmi-1 Expression
Low 1.000
High 3.979 1.534-5.875 0.001
RR: Relative Risk; CI: Confidence Interval.
Table 5 Multivariate Cox regression analysis of potential
prognostic factors for breast cancer patients
RR 95% CI P-value
Clinical Stage
I1
II 4.378 0.584-32.793 0.151
III 6.322 0.832-48.209 0.075
IV 12.948 1.688-99.333 0.014
PR Presence
Negative 1
Positive 0.539 0.344-0.845 0.007
Bmi-1 Expression
Low 1
High 1.708 1.213-3.087 0.042
RR: Relative Risk; CI: Confidence Interval.
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Page 9 of 23Figure 4 The exogenous expression of Bmi-1 promotes the motility and invasiveness of immortalized HMECs. (A) The endogenous
expression of Bmi-1 was detected in breast cancer cells and immortalized HMECs by immunoblotting. (B) The overexpression of Bmi-1 in
transfected immortalized HMECs was confirmed by RT-PCR and immunoblotting. GAPDH and anti-a-Tubulin were used as loading controls,
respectively. (C) Bmi-1 did not affect the proliferation of immortalized HMECs. (D) The invasive properties induced by EGF and Insuline were
analyzed by an invasion assay using Matrigel-coated Boyden chambers and scored under a light microscope (200X). (E) A wound was produced
and monitored at 0, 12, and 24 hours as the cells moved and filled the damaged area in serum-free medium (200X). The data were plotted as
the average number of cells per field of view (***P < 0.001).
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Page 10 of 23shBmi-12# cells were histologically similar to those from
controls, as assessed by hematoxylin and eosin staining
and reviewed by a veterinary pathologist (Figure 6A, D).
The xenografts from MDA-MB-435S/shScr cells invaded
the adjacent muscles deeply, whereas, the MDA-MB-
435S/shBmi-12# cells showed reduced invasiveness
(Figure 6A). The repression of Bmi-1 not only reduced
the volume and weight of the xenografts but also delayed
tumor occurrence (Figure 6B, C). Western blotting con-
firmed the persistent knockdown of Bmi-1 in the xeno-
graft tissues (Figure 6D). Necropsy revealed large
fulminant gross metastatic lesions in the lungs, involving
large portions of all lung lobes in eight out of ten mice
injected with the MDA-MB-435S/shScr cells. In contrast,
only small and limited metastatic lesions were observed
in the lungs of five out of ten mice injected with the
MDA-MB-435S/shBmi-12# cells (Figure 6E). However,
injection of MCF-10A/Bmi-1 cells neither formed xeno-
grafts in the fat pad nor caused metastatic lesions in
nude mice, even if SCID mice were used (data not
shown). These results indicated that overexpression of
Bmi-1 was not sufficient for the fully malignant transfor-
mation of immortalized HMECs, whereas knockdown of
Bmi-1 strongly slowed tumor progression and repressed
spontaneous lung metastasis in nude mice.
The expression of epithelial and mesenchymal markers
was altered by Bmi-1
The expression of EMT markers was analyzed to address
the mechanism of Bmi-1-facilitated breast cancer metas-
tasis. Although no EMT-associated morphological
changes were observed in Bmi-1 overexpressing and
knockdown cells, overexpression of Bmi-1 repressed
epithelial markers, such as E-cadherin and b-Catenin,
and up-regulated mesenchymal markers such as Vimen-
tin and Fibronectin. Conversely, the knockdown of Bmi-1
inhibited the expression of Vimentin and Fibronectin but
partially rescued the expression of b-Catenin (Figure 7A).
E-cadherin was not detected in MDA-MB-435S cells in
the present study, owing to its unique properties [49]. To
further validate the role of Bmi-1 in EMT, mRNA levels
of Bmi-1 and E-cadherin were measured in 34 breast
cancer tissues and in paired non-cancerous tissues from
the same patients by real-time PCR. As shown in Figure
7B, Bmi-1 was strongly up-regulated in breast cancer tis-
sues compared with paired non-cancerous tissues,
whereas E-cadherin was markedly down-regulated. Addi-
tionally, an inverse correlation was found between Bmi-1
and E-cadherin at the transcriptional level. To further
decipher the role of Bmi-1 in the invasion and metastasis
of breast cancer, EMT markers were analyzed in primary
xenografts and spontaneous metastatic lung lesions by
immunohistochemistry. As shown in Figure 8, Bmi-1
repression enhanced the expression of b-Catenin and
concomitantly reduced the expression of Fibronectin in
primary xenografts and metastatic lung lesions. As
demonstrated above, Bmi-1 is negatively correlated with
the expression of E-cadherin, which is important for
EMT in breast cancer.
Bmi-1 activates the Akt/GSK-3b/Snail pathway
Consistent with our previous reports that Bmi-1 could
regulate Akt activity in breast cancer cells [50,51] and the
Akt/GSK-3b/Snail pathway in NPC cells [27], the overex-
pression of Bmi-1 facilitated the expression of phosphory-
lated Akt. Moreover, the knockdown of Bmi-1 inhibited
the expression of phosphorylated Akt, but total Akt
remained unaffected (Figure 9A). As anticipated, the
expression of Snail and phosphorylated GSK-3b was up-
regulated by Bmi-1 overexpression and down-regulated by
Bmi-1 knockdown, but the levels of total GSK-3b
remained unaffected (Figure 9A). Nevertheless, the tran-
scriptional level of Snail was not affected by Bmi-1 overex-
pression (data not shown), suggesting that the modulation
of Snail might be due to a post-transcriptional modifica-
tion. Bmi-1 could extend the half-life of Snail in NPEC
cells by directing the subcellular localization, as demon-
strated by our previous data [27]. Therefore, we analyzed
the localization of Snail in MCF-10A cells. As shown in
Figure 9B, Snail could be detected in the nucleus and cyto-
plasm of the controls, but it was primarily localized in the
nucleus of the Bmi-1-transfected cells. Collectively, it
appears that Bmi-1 induces the activation of Akt and the
inactivation of GSK-3b by phosphorylation, facilitates the
stabilization and nuclear translocation of Snail, and finally
results in the deregulation of EMT markers, thus promot-
ing the migration and invasion of breast cancer cells.
Discussion
Breast cancer, a common malignant disease in women,
is prone to invade into adjacent regions and to metasta-
size to lymph nodes and distant organs. To develop
novel treatments and cures, it is imperative to address
the factors underlying tumorigenesis, invasion and
metastasis. In this study, we identified and functionally
characterized Bmi-1 as an important player in breast
cancer progression. The current study first illustrated
the expression of Bmi-1 in primary breast cancer tissues,
followed by demonstrating the association between the
Bmi-1 expression and clinicopathologic parameters and
finally addressed the role of Bmi-1 in breast cancer
prognosis in a large series of 252 samples. In this study,
differential expression of Bmi-1 was detected between
primary cancer tissues and the matched adjacent non-
cancerous tissues. Bmi-1 expression was significantly
up-regulated in breast cancer tissues compared with the
adjacent non-cancerous tissues, which was echoed by
our previous reports [15,50]. Only 35.9% of matched
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Page 11 of 23Figure 5 Suppression of endogenous Bmi-1 inhibits cellular motility, invasion and transformation. (A) Bmi-1 expression was confirmed
by RT-PCR and immunoblotting. It was dramatically decreased by RNA interference in MDA-MB-435S cells. (B) The Bmi-1 knockdown did not
alter the proliferation of MDA-MB-435S. (C) The mobility was measured by testing the rate of wound closure at 0, 8, 16 hours (200X). (D) The
invasive properties induced by FBS were analyzed by using the Matrigel-coated Boyden chamber assay (400X, ***P < 0.001). (E) Anchorage-
independent growth was measured in soft agar (200X, ***P < 0.001). (F) The acini formation of cells was tested in Matrigel culture (200X).
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Page 12 of 23Figure 6 Suppression of endogenous Bmi-1 slows down tumorigenesis and decreases lung metastasis in nude mice. (A) H&E staining
confirmed the invasiveness of the primary xenografts by analyzing tumor cell encroachment into adjacent muscle (100X and 400X). (B) The
initiation and growth of primary xenografts were determined by measuring the average tumor volume (*P = 0.038), (C) the tumor size and
average weight of primary xenografts (*P = 0.041). (D) Bmi-1 expression in the primary xenografts was detected by immunoblotting (1 and 2
were abbreviated from sample 1 and sample 2). (E) The number of spontaneous lung metastatic lesions in mice (N = 10 per group) was
analyzed by counting ten serial sections from each sample (*P = 0.036).
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Page 13 of 23adjacent non-cancerous tissues displayed the high Bmi-1
expression, whereas as many as 72.2% of the cancer tis-
sues were defined by high Bmi-1 expression. The inci-
dence of high Bmi-1 expression shown in this study was
much higher than previously demonstrated (53.2%) [19].
The difference may reflect differences in Bmi-1 status in
the samples used in different studies, which obtained tis-
sue samples from patients with different disease stages,
or samples from different populations. As shown in
Additional File 2, table S2, 46.4% of the Chinese samples
recruited in our study were from the early stage (I,II),
while 75.8% of Korean samples used in Choi’ss t u d y
w e r ef r o mt h ee a r l ys t a g e( I , I I )[ 1 9 ] .I na d d i t i o n ,n o
samples of stage □ were recruited in Choi’s study [19].
Furthermore, the difference may come from variations
in antigen retrieval, antibody dilution, development time
and the positive criteria adjusted, especially the score of
the positive number (Additional File 3, 4, 5, Table S3,S4,
S5). For example, we used EDTA buffer to retrieve anti-
gen in our research, as opposed to citrate buffer used in
Choi’s study [19]. In addition, the development time in
our study was 10 min compared with 5 min in Choi’s
study [19]. The criteria used in the immunohistochemis-
try varied in different studies. Choi et al. tested Bmi-1
expression by tissue microarray, which might not be a
good representative of the whole paraffin-embedded tis-
sue. Furthermore, cells were considered positive for
Bmi-1 only when nuclear staining was observed [19].
However, both nuclear and cytoplasm staining were
observed in our samples. However, to further confirm
Bmi-1 expression in breast cancers, multi-center studies
are required.
We also compared the Bmi-1 mRNA expression in 34
paired tissues, including breast cancer and matched adja-
cent non-cancerous tissues. There was a significant differ-
ential between the breast cancer tissues and the adjacent
non-cancer tissues, which corresponded to the protein
levels in the tissues. In our analysis, high Bmi-1 expression
showed an obvious correlation with larger tumor size,
lymph node involvement, organ metastasis and advanced
clinical stage. Over 90% of the late-stage (stages III/IV)
samples showed high expression, whereas less than 50% of
the early-stage (stagesI/II) samples showed high expres-
sion. These results revealed that higher Bmi-1 expression
was related to more aggressive behavior, which was further
supported by its expression in distant metastases. Of
patients without distant metastasis, 67.1% showed high
Bmi-1 expression, which is in contrast to 95.6% of patients
with distant metastasis. These studies indicated that a high
level of Bmi-1 protein might contribute to the invasion
Figure 7 Bmi-1 regulates EMT markers. (A) The expression of the
indicated proteins was analyzed by immunoblotting. Anti-a-Tubulin
was the loading control. (B) Top: The mRNA of Bmi-1 and E-
cadherin were compared between the breast cancer tissues and the
adjacent non-cancer tissues (**P = 0.001, *P = 0.042). Bottom: The
converse relationship between Bmi-1 and E-cadherin was plotted
(Spearman’s rho = -0.418, *P = 0.041).
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Page 14 of 23and progression of breast cancer. Although only 35.9% of
the adjacent non-cancerous tissues displayed high Bmi-1
expression, 69.2% stained positive for Bmi-1. Because
hyperplasia is known to occur often in adjacent non-can-
cerous tissues, we speculated that the Bmi-1 staining had
originated from hyperplasia.
In this study, the Bmi-1 protein seemed to localize in the
nucleus of the breast cancer cells and in the cytoplasm of
the non-cancer cells. It has been reported that phosphory-
lation can explain differential subcellular localization of
some of the polycomb family genes, such as Nervous Sys-
tem Polycomb 1(NSPc1) and M33 [52,53]. Previously, it
has been reported that there is a rich proline/serine region
at the carboxyl terminus of the Bmi-1 protein, where
phosphorylation often occurs [54]. However, whether the
phosphorylation of Bmi-1 is a direct cause or merely asso-
ciated with the nuclear-cytoplasm shuttling events remains
to be determined. It is also important to note that Bmi-1
predicted poor prognosis in breast cancer, in accordance
with other reports [21,24,55-58]. In addition, there were
significantly different outcomes between the patients
expressing high and low levels of Bmi-1 by subset analysis,
which suggested that Bmi-1 may be used to predict the
clinical outcome. In addition, it provides a potential thera-
peutic target for the future treatment of breast cancer.
In our study, Bmi-1 was not significantly correlated with
ER and PR expression, which is consistent with a previous
report indicating that Bmi-1 mRNA expression had no sig-
nificant correlation with ER or PR expression [20], but it is
inconsistent with other previously-published data [15,18,59].
Figure 8 Suppression of endogenous Bmi-1 reversed EMT markers in nude mice. H&E staining indicated the similarity of histopathology of
primary xenografts and lung metastases in two groups of mice. The indicated proteins were analyzed by immunohistochemistry. Bmi-1 and
Fibronectin detected in both primary xenografts and lung metastasis were down-regulated, whereas, b-Catenin was up-regulated in the MDA-
MB-435S/shBmi-12# group compared with the MDA-MB-435S/shScr group.
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observed between Bmi-1 expression and survival when ER
or PR was included in our analysis. ER
+ cancer cells depend
on estrogen for their growth, so they can be treated with
drugs that block the effect of estrogen. Patients with
ER present were offered adjuvant hormone therapy in our
study. High Bmi-1 expression was associated with unfavor-
able survival, irrelevant to ER or PR presence, indicating that
hormonal therapy did not affe c tt h ep r o g n o s t i cr o l eo f
Bmi-1. Patients with metastatic breast cancer may take
Figure 9 Bmi-1 modulates Akt/GSK3b/Snail pathway. (A) Cell extracts were analyzed by immunoblotting with antibodies against the
indicated proteins. Anti-a-Tubulin was used as the loading control. (B) Immunofluorescence identified the effect of Bmi-1 on the subcellular
localization of Snail proteins (Green) in MCF-10A cells.
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Page 16 of 23tamoxifen for varying lengths of time, depending on the can-
cer’s response to this treatment and other factors [60].
When used as adjuvant therapy for early-stage breast cancer,
tamoxifen is generally prescribed for five years. However, the
ideal length of treatment with tamoxifen is not known.
Thus, different lengths of treatments with tamoxifen
depending on the individual responses to it may have
resulted in a different outcome in our study. In addition, the
combination of endocrine therapy with other therapy
remains a research issue [61]. Generally, patients who are
positive for HER-2 had a worse prognosis [62]. However,
these 252 patients did not receive anti-HER-2 therapy
because Herceptin (a humanized monoclonal antibody
directed at the HER2 ectodomain) was not in use at that
time in China. Although there was no significant correlation
between Bmi-1 expression and HER-2 status, patients with
high Bmi-1 expression showed poor survival stratified by
HER-2, just as with ER and PR. Having demonstrated the
significance of Bmi-1 in the overall survival prognosis of
breast cancer patients, it will be our next focus to investigate
the prognostic value of Bmi-1 in terms of disease-free survi-
val and cancer-specific survival. Additionally, a possible cor-
relation between Bmi-1 expression and outcome after
hormonal therapy and chemotherapy warrants investigation
and would require a large number of samples.
Metastatic relapse remains a major challenge in breast
cancer management. Many factors are involved in
tumor progression, including changes in cell adhesion,
cell communication, increased migration or motility and
invasiveness [63]. In this study, Bmi-1 was shown to
contribute to each of these events in clinical samples
and in cell lines. To address the role of Bmi-1 in tumor
progression, Bmi-1 was overexpressed in two immorta-
lized HMEC lines, 76N-TERT and MCF-10A. Conver-
sely, RNA interference was used to decrease the
expression of Bmi-1 in MDA-MB-435S, an estrogen-
independent breast cancer cell line derived from a mam-
mary ductal carcinoma [64]. MDA-MB-435S cells can
form progressively growing tumors in the lungs and
regional lymph node metastases following injection into
the mammary fat pad of 3-4 week old athymic nude
mice [65]. In this study, the overexpression of Bmi-1
alone could not fully transform 76N-TERT or MCF-10A
cells. Furthermore, Bmi-1 expression did not alter the
morphology of these cells in 3-D Matrigel culture. In
addition, the spindle-shaped phenotype and non-contact
inhibited, disorganized proliferation of MDA-MB-435S
cells [66] was not altered by the inhibition of Bmi-1.
This result was in accordance with a previous observa-
tion that Bmi-1 alone did not result in an EMT pheno-
type in MCF-10A cells, but that co-overexpression of
Bmi-1 and Ras readily did [28]. Additionally, we exam-
ined the potential oncogenic role of Bmi-1 by the injec-
tion of Bmi-1-expressing MCF-10A cells into mice.
Even injection of 1 × 10
7 MCF-10A/Bmi-1 cells did not
result in tumor formation after two months in nude or
SCID mice. Unlike in immortalized NPECs, Bmi-1 alone
was not sufficient to induce the typical EMT morpholo-
gical changes in immortalized HMECs. The induction of
morphological alterations associated with EMT by Bmi-
1 might depend on the cell type. To our knowledge, the
immortalized NPECs were derived from squamous
epithelium, whereas the immortalized HMECs origi-
nated from glandular epithelium. In addition, the mor-
phologic changes of EMT might be directed by
differential oncogene activation. Ras [67] and ILEI [68]
can lead to EMT, tumor formation and metastasis.
These results suggest that additional oncogenic events,
such as H-Ras expression or loss of expression of tumor
suppressor genes could be involved in the EMT of
immortalized HMECs induced by Bmi-1. Thus, we sug-
gest that Bmi-1-induced EMT is cell-type specific.
One thing worth mentioning is that although E-cad-
herin, a useful molecule to protect breast cancer from
metastasis [69], was not detected in MDA-MB-435S
cells, the MDA-MB-435S/shBmi-1 cells still manifested
reduced motility. To our knowledge, several highly
metastatic cancer cells, including MDA-MB-435S cells,
lack E-cadherin expression [70]. Low E-cadherin expres-
sion can be caused by gene mutations or promoter
methylation [71,72], as well as by regulation by inhibi-
tors such as Twist [73]. After EMT, mesenchymal
FosER cells completely lacked E-cadherin but formed
neither tumors nor metastases [74], indicating that loss
of E-cadherin expression might be necessary but not
sufficient for tumor progression. Similarly, although E-
cadherin expression was decreased by Bmi-1 overexpres-
sion, the HMECs did not form tumors in the current
study. As we know, besides E-cadherin, many other
genes are involved in breast cancer metastasis, such as
b-Catenin [75] and N-cadherin [76]. Numerous studies
have linked aberrant E-cadherin with the development
of metastasis in cancer [77], whereas other studies have
presented different results indicating that cells from dis-
tant metastases and nodal involvement consistently
expressed E-cadherin, often at higher levels than in the
primary tumor [78,79]. It appears that translational reg-
ulation and post-translational events are probable
mechanisms for E-cadherin re-expression [80]. It is pos-
sible that loss of E-cadherin is a transient phenomenon
that allows malignant cells to invade vascular channels
and tissues. Disseminated mesenchymal cancer cells
seem to undergo the reverse transition, mesenchymal-
epithelial transition (MET), at the metastatic site to
allow micrometastases to give rise to a secondary neo-
plasm. In this regard, cancer cells from the secondary
site re-express markers of epithelial cells such as E-cad-
herin. However, whether re-expression of E-cadherin
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static site, and if so, what is the underlying mechanism
requires further investigation. In addition, our data sug-
gest that Bmi-1 has a critical effect on breast cancer
tumorigenesis and lung metastasis. We believe that this
is an extremely important observation in terms of study-
ing breast cancer lung metastasis because the lung is the
most common location of breast cancer metastasis. We
suggest that Bmi-1 contributes to the metastasis of
breast cancer. Crosstalk between different pathways,
recognized as a mechanism for expanding the cellular
communication signaling network, is currently receiving
increased attention. The activated PI3K/Akt pathway
has been well documented in various human malignan-
cies and sometimes correlates with an aggressive pheno-
type [81]. Our previous data also indicated that down-
regulation of Bmi-1 by an RNA interference (RNAi)
approach was accompanied by down-regulation of Akt/
protein Kinase B (PKB) activity [50]. In our current
study, we demonstrated that Bmi-1 induced invasion,
which might be associated with activation of the Akt
pathway in breast cancer cells. As metastasis can occur
in early stages of tumor development, some genes may
constantly regulate tumor development. They may not
only facilitate primary tumor initiation but also promote
tumor transformation and metastasis [82]. The expres-
sion pattern of Bmi-1, together with functional studies,
indicate that Bmi-1 plays a prominent role in breast
cancer progression and metastasis and opens the door
for future studies addressing Bmi-1-targeted therapy in
breast cancer.
Conclusions
In summary, breast cancer shows a high prevalence of
Bmi-1 expression, which is significantly correlated with
aggressive features and unfavorable prognosis. Assess-
ment of Bmi-1 expression might help to identify a high-
risk subgroup of breast cancers. Furthermore, Bmi-1
plays a crucial role in invasion and metastasis by modu-
lating the Akt/GSK-3b/Snail pathway and the expression
of EMT markers in breast cancer.
Materials and methods
Tissue Samples
Paraffin-embedded breast cancer samples were obtained
from 252 female Chinese patients (median age: 47 years,
range: 26-78 years) diagnosed with breast cancer in
1999-2001 at Cancer Center, Sun Yat-sen University,
Guangzhou, China. Of the 252 breast cancer samples,
39 matched adjacent non-cancerous tissues were
obtained from the above-mentioned patients. All of the
samples were treated by surgical excision. Among them,
239 cases had follow-up records and the median follow-
up time was 59 months (range: 4-78 months). Clinical
and pathologic factors were evaluated, including age,
TNM classification, clinical stage, presence of steroid
receptors and HER-2 expression. HER-2 expression was
only analyzed in 159 cases, while the other samples
were not analyzed. A total of 147 cases were analyzed
for ER, PR and HER-2 expression. Thirteen cases were
missing records of patient age, survival time and survival
status, but included the TNM classification, clinical
stage, presence of steroid receptors and HER-2 expres-
sion. To use these clinical materials for research pur-
poses, prior patients’ consent and approval from the
Institute Research Ethics Committee were obtained. The
observation period was from 1999 to 2006. The clinical
stages of all the patients were classified according to the
2002 TNM staging of UICC (International Union
against Cancer).
Immunohistochemistry in Clinical Samples
The 4 μm paraffin-embedded sections of breast cancer
were deparaffinized with xylene, rehydrated and treated
with 3% hydrogen peroxide in methanol to quench the
endogenous peroxidase activity. Subsequently, antigen
retrieval was performed by heating in a microwave oven
with EDTA (pH 8.0). One percent bovine serum albumin
(BSA) was used to block non-specific binding, followed by
incubation of the sections with a mouse monoclonal anti-
Bmi-1 antibody (1:100, Upstate Biotechnology, Lake Pla-
cid, USA) overnight at 4°C. After washing with phosphate
buffered saline, sections were incubated with biotinylated
secondary antibody, followed by a further incubation with
the streptavidin-horseradish-peroxidase complex. The sec-
tions were then immersed in 3, 3’-Diaminobenzidine
(DAB) for 10 min, counterstained with 10% Mayer’s
hematoxylin, dehydrated, and mounted in crystal mount.
The primary antibody was replaced by non-immune
mouse IgG of the same isotype to serve as negative con-
trols. To minimize variations in the immunopositive cells,
all sections were stained in DAB for the same amount of
time. Two pathologists, blinded to the clinical outcome,
scored the results of the staining independently. Measure-
ments of ER, PR and HER-2 were routinely performed as
previously described [83].
Cell lines, Vectors and Plasmids
Immortalized HMECs (76N-TERT and MCF-10A) and
radiation-transformed cells (76R-30) were cultured in
Keratinocyte-SFM medium (Invitrogen, Grand Island,
NY) supplemented with bovine pituitary extract. MDA-
MB-435S cells were maintained in DMEM/F12 (Gibco)
supplemented with 10% fetal calf serum (HyClone). SK-
BR-3, ZR-75-30 and BCAP-37 cells were grown in
RPMI 1640 with 10% fetal calf serum. The pMSCV-
B m i - 1a n dB m i - 1s h o r th a i r p i nR N A( s h R N A i )c o n -
structs were generated as described previously [21,51].
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fected into 76N-TERT and MCF-10A cells, as described
previously [13]. The plasmid with shBmi-1 was intro-
duced into MDA-MB-435S cells, which showed strong
ability to metastasize [48]. The sequences of shRNA
were as follows: shBmi-1 1# GUUCACAAGACCAGAC-
CAC and shBmi-1 2# GACCAGACCACUACUGAAU
[51]. pMSCV and PRS plasmids were used as controls.
All retrovirally infected cells were maintained under
Puromycin selection and used as stable cells.
RT-PCR, Real-time PCR and Western Blot Analysis
Total RNA from fresh tissues and cell lines was isolated
using Trizol reagent (Invitrogen, Grand Island, NY),
according to the manufacturer’s instructions, and 1.0 μg
of total RNA treated with DNAase was used for cDNA
synthesis by random hexamers. Genes were amplified by
PCR from cDNA. The forward primer for Bmi-1 was 5-
’CTGGTTGCCCATTGACAGC’-3, the reverse primer
was 5-’CAGAAAATGAATGCGAGCCA’-3. The for-
ward primer for GAPDH was 5-’AGCCGTTCGGAG-
GATTATTCG’-3, the reverse primer was CTTCTCCT
CAGCAGCCAGAG. The products were analyzed by
agarose gel electrophoresis and confirmed by appropri-
ate size.
Real-time PCR was carried out using an ABI PRISM
7500 Sequence Detection System (Applied Biosystems,
Foster City, CA). Reactions were performed in triplicate
repeats in two independent experiments. The geometric
mean of the GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase) housekeeping gene was used as an internal
control to normalize the variability in expression levels.
The forward primer for Bmi-1 was 5-’CTGGT TGCCC
ATTGACAGC’-3, the reverse primer was 5-’CAGAAAA
TGAATGCGAGCCA’-3 and the probe was FAM-CAG
CTCGCTTCAAGATGGCCGC-TAMRA. The forward
primer for E-cadherin was 5-’GAACAGCACGTACA-
CAGCCCT’-3, the reverse primer was 5-’GCAGAAG
TGTCCCTGTTCCAG’-3 and the probe was FAM-A
TCATAGCTACAGACAATGGTTCTCCAGTTGCT-
TAMRA. The forward primer for GAPDH was 5-’GACT
CATGACCACAGTCCATGC’-3, the reverse primer was
5-’AGAGGCAGGGATGATG TTCTG’-3 and the probe
was FAM-CATCACTGCCACCCAGAAGACTGTG-
TAMRA.
Immunoblotting was carried out as described [84]. The
blots were probed with mouse anti-Bmi-1, anti-E-cadherin,
anti-b-catenin, anti-fibronectin and anti-vimentin antibo-
dies (BD, Transduction Laboratories, Lexington, UK) as
well as with rabbit anti-p-GSK, anti-t-GSK (Cell Signaling
Technology, Inc. USA), anti-snail (Abcam, Cambridge
Science Park, Cambridge, UK), anti-p-Akt (Santa Cruz
Biotechnology, CA, USA) and goat anti-t-Akt (Santa Cruz
Biotechnology, CA, USA) antibodies. The membranes were
stripped and re-probed with mouse anti-a-tubulin (Sigma
Aldrich, Inc. St Louis, Missouri, USA) to confirm equal
loading of the samples.
Wound Healing Assay
Cells were seeded in six-well plates and cultured under
permissive conditions until 90% confluence. After star-
ving the cells for 24 h in medium without EGF or FBS,
the confluent cell monolayer was lightly and quickly
scratched with a pipette tip to produce a straight line.
The debris was removed and the edge of the scratch
was smoothed with PBS washing. The wound healing
assays were done in growth factor-free medium, further
excluding any effect due to a potential proliferation dif-
ference. The open gap was then inspected and photo-
graphed microscopically at indicated times, and is
shown in the Figures at a 200X magnification. The
migration activity was calculated as the number of cells
entering into the rectangle. Experiments were repeated a
minimum of three times.
Proliferation Assay
1×1 0
5 cells were plated on a P60 plate. Every 24 h,
cells were trypsinized and counted under a light micro-
scope at least three times until the sixth day. Experi-
ments were repeated a minimum of three times.
Boyden Chamber Assay
This assay measures the ability of cells to invade a
Matrigel matrix overlying a membrane containing 8-μm
pores. Cells were seeded in medium deprived of EGF or
FBS in the top chamber (BD), whereas medium contain-
ing EGF or FBS was added to the bottom chamber.
After an appropriate cultivation time, the chambers
were fixed with 1% paraformaldehyde and stained with
hematoxylin. The number of cells in ten random fields
of view was enumerated at 200X or 400X magnification
for each filter. Three independent experiments were per-
formed and the data are presented as the mean ± SD.
Three Dimensional Matrigel Culture
Matrigel (1.2 mg/ml, BD) was coated on the bottom of a
24-well plate. After Matrigel polymerization, cells were
seeded into the well with growth medium containing 2%
Matrigel. The cells were cultivated at 37°C incubation
and alterations to the morphologic phenotype were
monitored at 200X magnification every other day.
Experiments were repeated a minimum of three times.
Anchorage-Independent Growth in Soft Agar
The soft agar assay was used to determine the propensity
for anchorage-independent growth. Cells were plated in a
60-mm dish using 2 ml of growth medium, including
0.33% agar on the top of a bottom layer containing 0.66%
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ium. Colonies were photographed and counted in ten
random fields of view at 200X magnification using light
microscopy. Each experiment was done in triplicate.
Confocal Immunofluorescence Microscopy
Cells were seeded onto glass slides for 24 h, washed
with PBS, fixed in 4% paraformaldehyde and permeabi-
lized with 0.5% Triton X-100 for five minutes. After
blocking with BSA, cells were stained with anti-snail pri-
mary antibody followed by FITC-conjugated anti-rabbit
IgG. To visualize the nucleus, 4’ 6-Diamidino-2-pheny-
lindole (DAPI) staining was also performed, as pre-
viously described [85]. Immunofluorescence was
detected by fluorescence microscopy (Olympus).
Mouse Injections, Necropsy, Histopathology
The ability to form tumors and metastasize was analyzed
by injecting cells with repressed Bmi-1 into nude mice.
Mice were bred and maintained under SPF conditions in
the Department of Animal Center, Cancer Center, Sun
Yat-Sen University, as approved by the China Care Com-
mittee Institute. Ten healthy female nude mice, which
w e r ef o u r -t os i x -w e e k so l d ,were randomly assigned to
each group. Each mouse was injected in the fat pad with
2×1 0
6 cells in PBS solution. Tumor growth was mea-
sured by caliper, and tumor volume was calculated
according to the formula: length × width
2 × 0.52, as
described previously [86]. All mice were sacrificed on the
sixth week after injection. The primary tumor and lung
tissues of each mouse were removed, weighed and
embedded in 10% paraffin. Each tissue was chopped into
small pieces. Total protein was extracted to detect Bmi-1
expression from the primary xenografts. Each section
from the primary xenografts and lung tissues was sub-
jected to H&E staining, according to standard protocols,
for histological examination and metastasis evaluation.
The nodes of lung metastasis were quantified by counting
metastatic lesions in ten sections (10 μmp e rs e c t i o ni na
series). Data were collected by counting the total num-
bers of metastatic lesions from ten sections. Sections of
primary tumors and lung lesions were used to detect the
expression of the markers (Bmi-1, b-catenin, fibronectin)
by IHC, as described previously.
Statistical analysis
The Chi-Square test was employed to evaluate the dif-
ferences in Bmi-1 expression between the two categories
of tissues. For assessment of the correlation between
clinical features and Bmi-1 expression in breast cancer,
P values were calculated by using the Chi-Square test or
the Fisher’s exact test. Relative risks (RRs) of death asso-
ciated with Bmi-1 expression and other predictive
variables were estimated by using the univariate and
multivariate Cox proportional hazards model. The over-
all survival curve was plotted using Kaplan-Meier survi-
val analysis and compared by the log-rank test. Result
variations for the chamber invasion assays, wound heal-
ing assay, soft agar assay, tumor volume, tumor weight
and lung metastasis lesions in mice, described as mean
± SD, were assessed using the two-tailed Student’s t
test. A value of P < 0.05 was considered significant (two
tailed) by using SPSS 16.0.
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